Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype.


Journal

Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916

Informations de publication

Date de publication:
Mar 2022
Historique:
revised: 02 12 2021
received: 13 09 2021
accepted: 06 12 2021
pubmed: 30 12 2021
medline: 15 3 2022
entrez: 29 12 2021
Statut: ppublish

Résumé

The negative impact of haemophilia on social participation is well established in previous studies, however, the impact of Von Willebrand disease (VWD) on social participation has not been studied. To compare the social participation of a large cohort of VWD patients in the Netherlands with the general Dutch population. In addition, to identify factors associated with social participation in VWD. Patients participating in the "Willebrand in the Netherlands" study completed an extensive questionnaire on educational level, absenteeism from school or work, and occupational disabilities. Seven-hundred and eighty-eight VWD patients were included (mean age 38.9 years, 59.5% females), of whom 136 children < 16 years. Adult patients with type 3 VWD more often had a low educational level (52.9%) compared to type 1 (40.2%), type 2 VWD (36.8%) and the general population (36.4%) (p = .005). Moreover, in patients aged ≥16 years the days lost from school and/or work in the year prior to study inclusion differed significantly between the VWD types (p = .011). Using negative binomial regression analysis, the occurrence of bleeding episodes requiring treatment in the year preceding study inclusion was significantly associated with the number of days lost from school and/or work among patients aged ≥16 years. Multivariable logistic regression analysis showed that a higher total bleeding score, older age and presence of at least one comorbidity were significantly associated with occupational disability in patients aged ≥16 years. Our study shows that social participation was lower in type 3 VWD and VWD patients with a more severe bleeding phenotype.

Identifiants

pubmed: 34964530
doi: 10.1111/hae.14475
pmc: PMC9304182
doi:

Substances chimiques

von Willebrand Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-285

Subventions

Organisme : Dutch Haemophilia Foundation
Organisme : CSL Behring

Informations de copyright

© 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd.

Références

J Obstet Gynaecol. 2019 Feb;39(2):288-290
pubmed: 30207499
Thromb Haemost. 2011 Nov;106(5):885-92
pubmed: 21947221
J Thromb Haemost. 2006 Apr;4(4):766-73
pubmed: 16634745
Thromb Haemost. 2012 Oct;108(4):683-92
pubmed: 22918553
Haemophilia. 2015 May;21(3):e185-e192
pubmed: 25854528
Blood. 2008 Feb 15;111(4):1811-5
pubmed: 17986664
Blood. 2015 May 07;125(19):3006-13
pubmed: 25673639
J Thromb Haemost. 2006 Oct;4(10):2103-14
pubmed: 16889557
Haemophilia. 2008 May;14(3):415-22
pubmed: 18218013
J Thromb Haemost. 2011 Mar;9(3):502-9
pubmed: 21166992
Am J Hematol. 2015 Dec;90(12):1142-8
pubmed: 26375306
Haemophilia. 2004 Jul;10(4):360-6
pubmed: 15230950
J Thromb Haemost. 2014 Jul;12(7):1066-75
pubmed: 24750783
Haemophilia. 2019 Jan;25(1):101-108
pubmed: 30427095
J Thromb Haemost. 2008 Dec;6(12):2062-6
pubmed: 18983516
Haemophilia. 2022 Mar;28(2):278-285
pubmed: 34964530
Haemophilia. 2016 Jan;22(1):46-53
pubmed: 26207763
Haematologica. 2017 Sep;102(9):1486-1493
pubmed: 28572165
Blood Adv. 2021 Jan 12;5(1):280-300
pubmed: 33570651
J Thromb Haemost. 2010 Jul;8(7):1492-9
pubmed: 20345712
N Engl J Med. 2016 Nov 24;375(21):2067-2080
pubmed: 27959741

Auteurs

Eva K Kempers (EK)

Department of Haematology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Calvin B van Kwawegen (CB)

Department of Haematology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Joke de Meris (J)

Netherlands Haemophilia Society, Leiden, The Netherlands.

Saskia E M Schols (SEM)

Department of Haematology, Radboud University Medical Centre, Nijmegen and Haemophilia Treatment Centre Nijmegen-Eindhoven-Maastricht, Nijmegen, The Netherlands.

Karin P M van Galen (KPM)

Department van Creveldkliniek, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

Karina Meijer (K)

Department of Haematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Marjon H Cnossen (MH)

Department of Paediatric Haematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Johanna G van der Bom (JG)

Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands.
Jon J. van Rood Centre for Clinical Transfusion Medicine, Sanquin Research, Leiden, The Netherlands.

Karin Fijnvandraat (K)

Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Paediatric Haematology, Amsterdam, The Netherlands.
Sanquin Research, Department of Molecular Cellular Haemostasis, Amsterdam, The Netherlands.

Jeroen Eikenboom (J)

Department of Internal Medicine, Division of Thrombosis and Haemostasis, Leiden University Medical Centre, Leiden, The Netherlands.
Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Centre, Leiden, The Netherlands.

Ferdows Atiq (F)

Department of Haematology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Frank W G Leebeek (FWG)

Department of Haematology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH